Thank you to those of you who attended the 2017 Tisch MSRCNY Patient Symposium. We are happy to provide above, the citrus butter salmon recipe featured in Dr. Bates' presentation, Recipe for Success!
We are just days away from the 20th Annual Tisch MS Research Center Patient Education Symposium. Don't miss this free event open to all people with MS, their family, friends and caregivers. Register at: www.tischms.org/events
Tisch MS Research Center of New York (Tisch MSRCNY) will hold its' 20th Annual MS Patient Education Symposium on Sunday, October 22nd at the New York Hilton in Midtown. The doors open at 8:30am and the program will be from 9:30am to 1:00pm. To register please visit: www.tischms.org/events We are...
Ocrelizumab (OCREVUS™), an anti-B cell therapy has been approved by the FDA as of March 28th 2017, for the treatment of Relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). This treatment is highly effective for RRMS, based on the data from the Phase III...
Tisch MSRCNY is preparing for construction to commence January 2017 of a state-of-the-art stem cell facility on our 3rd floor. This could not have been done without the generosity of our supporters. The build-out of our new research laboratory enables Phase II of the Tisch MSRCNY FDA-approved stem...
Did you know you’re leaving valuable donations toward a Future Without MS on the table every time you shop on Amazon without connecting to Amazon Smile? What is AmazonSmile? AmazonSmile is a simple and automatic way for you to support the Tisch MS Research Center at no cost to you. When you log on...
Stars Come Out to Help End Multiple Sclerosis at Tisch MS Research Center of New York’s Future Without MS Gala New York, NY- November 1, 2016- The Tisch MS Research Center of New York (Tisch MSRCNY) announced today that their continued efforts to raise $10 million for the Center’s unprecedented...
The following article describes the first clinical use of of intrathecal MSC-NPs in 6 patients with progressive MS. An average followup of 7 years demonstrated both short and long term safety of the treatment. Four of the six patients showed a measurable clinical improvement following MSC-NP...